| Identification | Back Directory | [Name]
COH-29 | [CAS]
1190932-38-7 | [Synonyms]
COH-29
181687
CS-2737
COH-29; COH 29
RNR Inhibitor COH29
N-(4-(3,4-dihydroxyphenyl)-5-phenylthiazol-2-yl)-3,4-dihydroxybenzamide
Benzamide, N-[4-(3,4-dihydroxyphenyl)-5-phenyl-2-thiazolyl]-3,4-dihydroxy- | [Molecular Formula]
C22H16N2O5S | [MDL Number]
MFCD28502212 | [MOL File]
1190932-38-7.mol | [Molecular Weight]
420.44 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:45.0(Max Conc. mg/mL);107.03(Max Conc. mM)
Ethanol:10.0(Max Conc. mg/mL);23.78(Max Conc. mM) | [form ]
Solid | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
COH29 (RNR Inhibitor COH29) is a potent ribonucleotide reductase (RNR) inhibitor with anticancer activity. COH29 inhibits α and β subunit of RNR with IC50s of 16 μM. | [in vivo]
COH29 results in a dose-dependent inhibition of MOLT-4 tumor xenograft growth with twice-daily oral dosing at 50 mg/kg and 100 mg/kg, which is pronounced by Day 12 of treatment. Similarly, 7 days of treatment of mice bearing TOV11D xenografts with 200, 300, or 400 mg/kg/day COH29 results in a dose-dependent inhibition of tumor xenograft growth. Tumor growth is significantly inhibited compared with the control group[1]. | [storage]
Store at -20°C | [References]
[1] Zhou B, et al. A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance.Cancer Res. 2013 Nov 1;73(21):6484-93. DOI:10.1158/0008-5472.CAN-13-1094
[2] Chen MC, et al. The Novel Ribonucleotide Reductase Inhibitor COH29 Inhibits DNA Repair In Vitro. Mol Pharmacol. 2015 Jun;87(6):996-1005. DOI:10.1124/mol.114.094987 |
|
| Company Name: |
ChemShuttle, Inc.
|
| Telephone: |
0510-83588313-811 18800520310 |
| Website: |
www.jiehuapharma.com/ |
|